Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo

11 Mar 2021

Abstract excerpt

Abstract In lung adenocarcinoma, oncogenic EGFR mutations co-occur with many tumor suppressor gene alterations; however, the extent to which these contribute to tumor growth and response to therapy in vivo remains largely unknown. By quantifying the effects of inactivating 10 putative tumor suppressor genes in a mouse model of EGFR-driven Trp53-deficient lung adenocarcinoma, we found that Apc, Rb1, or Rbm10...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33707235
DOI: 10.1158/2159-8290.cd-20-1385

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In VivoPMID 33707235Read ↗

Genetic determinants of <i>EGFR</i> -Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i>Semantic proximity Read ↗

A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung CancerSemantic proximity Read ↗

Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma.Semantic proximity Read ↗

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.Semantic proximity Read ↗

Phenotype-dependent subtyping exposes high MYC activity as a targetable dependency in LuAdSemantic proximity Read ↗

Transcriptional phenocopies of deleterious<i>KEAP1</i>mutations dictate survival outcomes in lung cancer treated with immunotherapySemantic proximity Read ↗

Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous.Semantic proximity Read ↗

The mutational landscape of <i>EGFR-</i> , <i>MYC-</i> , and <i>Kras-</i> driven genetically-engineered mouse models of lung adenocarcinomaSemantic proximity Read ↗

Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy.Semantic proximity Read ↗

A novel mouse cell line model reveals the tumor intrinsic and immune characteristics of EGFR-mutant lung cancer.Semantic proximity Read ↗

Quantitative <i>in vivo</i> analyses reveal a complex pharmacogenomic landscape in lung adenocarcinomaSemantic proximity Read ↗

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.